Please wait while the formulary information is being retrieved.
Drug overview for IMDELLTRA (tarlatamab-dlle):
Generic name: tarlatamab-dlle
Drug class: Antineoplastic - Immunotherapy, T-cell Engager
Therapeutic class: Antineoplastics
Tarlatamab-dlle, a bispecific delta-like ligand 3 (DLL3)-directed CD3 T-cell engager, is an antineoplastic agent.
No enhanced Uses information available for this drug.
Generic name: tarlatamab-dlle
Drug class: Antineoplastic - Immunotherapy, T-cell Engager
Therapeutic class: Antineoplastics
Tarlatamab-dlle, a bispecific delta-like ligand 3 (DLL3)-directed CD3 T-cell engager, is an antineoplastic agent.
No enhanced Uses information available for this drug.
DRUG IMAGES
No Image Available
The following indications for IMDELLTRA (tarlatamab-dlle) have been approved by the FDA:
Indications:
Extensive-stage small cell lung cancer
Professional Synonyms:
Extensive stage primary small cell carcinoma of lung
Indications:
Extensive-stage small cell lung cancer
Professional Synonyms:
Extensive stage primary small cell carcinoma of lung
The following dosing information is available for IMDELLTRA (tarlatamab-dlle):
No dose reduction for tarlatamab-dlle is recommended. See Tables 3 and 4 for recommended management of cytokine release syndrome (CRS) and neurologic toxicity including immune effector cell-associated neurotoxicity syndrome (ICANS), respectively, and Table 5 for cytopenias, infections, and other adverse reactions.
See Table 2 for recommendations on restarting tarlatamab-dlle after dose delays.
Guidelines for the management of neurologic toxicity are based on the Immune Effector Cell-Associated Encephalopathy (ICE) score. The manufacturer recommends that ICE assessments be performed if the patient is arousable. Assess orientation (oriented to year, month, city, hospital=4 points); naming (names 3 objects, e.g., point to clock, pen, button=3 points); following commands (e.g., "show me 2 fingers" or "close your eyes and stick out your tongue"= 1 point); writing (ability to write a standard sentence=1 point); and attention (count backwards from 100 by ten=1 point).
If patient is unarousable and unable to perform ICE assessment (Grade 4 ICANS)=0 points.
Table 3: Guidelines for Grading and Dosage Modification and Management of Cytokine Release Syndrome
CRS Grade Defining Symptoms Tarlatamab-dlle Management Dosage Modification Grade 1 Symptoms require Withhold Administer symptomatic tarlatamab-dlle symptomatic treatment only until event treatment (e.g., (e.g., fever resolves, then acetaminophen) >=100.4degrees resume for fever. without tarlatamab-dlle Consider hypotension or at the next dexamethasone 4 hypoxia).
scheduled dose. mg to 10 mg oral or IV (or equivalent). Taper steroids per standard of care guidelines.
Grade 2 Symptoms require Withhold Recommend and respond to tarlatamab-dlle hospitalization moderate until event for a minimum of intervention. resolves, then 24 hours with Fever resume cardiac telemetry >=100.4degreesF, tarlatamab-dlle and pulse hypotension at the next oximetry.
responsive to scheduled dose. Administer fluids not symptomatic requiring treatment (e.g., vasopressors acetaminophen) and/or hypoxia for fever. requiring low Administer flow nasal supplemental cannula or oxygen and IV blow-by.
fluids when indicated. Consider dexamethasone (or equiva lent) 8 mg oral or IV. Taper steroids per standard of care guidelines.
Consider tocilizumab (or equivalent) When resuming the next planned dose, monitor patients from the start of the tarlatamab-dlle infusion for 22 to 24 hours in an appropriate healthcar e setting. Grade 3 Severe symptoms Withhold In addition to defined as tarlatamab-dlle Grade 2 temperature until the event treatment: >=100.4degreesF resolves, then Recommend with hemodynamic resume intensive instability tarlatamab-dlle monitoring, e.g.,
requiring a at the next intensive care vasopressor (with scheduled dose. unit (ICU) care. or without For recurrent Administer vasopressin) Grade 3 events, dexamethasone (or and/or worsening permanently equivalent) 8 mg hypoxia or discontinue IV every 8 hours respiratory tarlatamab-dlle. up to 3 doses.
distress Taper steroids requiring high per standard of flow nasal care guidelines. cannula (>6 Vasopressor L/minute) or face support as ne mask. eded.
High flow oxygen support as needed. Recommend tocilizumab (or equivalent) Prior to the next dose, administer concomitant medications as recommended for cycle 1 day 1 and cycle 1 day 8 (see Premedication and Prophylaxis under Dosage and Administratio n). When resuming the next planned dose, monitor patients from the start of the tarlatamab-dlle infusion for 22 to 24 hours in an appropriate healthcare setting.
Grade 4 Life-threatening Permanently ICU care. Per symptoms defined discontinue Grade 3 as temperature tarlatamab-dlle. treatment.
>=100.4degreesF Recommend with hemodynamic tocilizumab (or instability equivalent) requiring multiple vasopressors (excluding vasopressin) and/or worsening hypoxia or respiratory distress despite oxygen administration requiring positive pressure.
Table 4: Guidelines for Management of Neurologic Toxicity including Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
ICANS Grade Defining Symptoms Tarlatamab-dlle Management Dosage Modifications Grade 1 ICE score 7-9 Withhold Supportive care. with no depressed tarlatamab-dlle level of until ICANS consciousness. resolves, then resume tarlatamab-dlle at the next scheduled dose.
Grade 2 ICE score 3-6 Withhold Supportive care. and/or mild tarlatamab-dlle Dexamethasone (or somnolence until ICANS equivalent) 8 to awakening to resolves, then 10 mg oral or IV. voice.
resume Taper steroids tarlatamab-dlle per standard of at the next care guidelines. scheduled dose. Monitor neurologic symptoms and consider consultation with neurologist and other specialists for further evaluation and management.
Monit or patients from the start of the tarlatamab-dlle infusion for 22 to 24 hours following the next dose of tarlatamab-dlle. Grade 3 ICE score 0-2 Withhold Recommend and/or depressed tarlatamab-dlle intensive level of until the ICANS monitoring, e.g.,
consciousness resolves, then ICU care. awakening only to resume Consider tactile stimulus tarlatamab-dlle mechanical and/or any at the next ventilation for clinical seizure scheduled dose. airway focal or If there is no protection.
generalized that improvement to Dexamethasone (or resolves rapidly Grade <=1 within equivalent) 10 mg or nonconvulsive 7 days IV every 6 hours seizures on EEG permanently or that resolve with discontinue methylprednisolon intervention tarlatamab-dlle. e (or equivalent) and/or focal or For recurrent 1 mg/kg IV every local edema on Grade 3 events, 12 hours. Taper permanently steroids per discontinue standard of car neuroimaging.
tarlatamab-dlle. e guidelines. Consider repeat neuroimaging (e.g., computed tomography (CT) or magnetic resonance imaging (MRI)) every 2-3 days if patient has persistent Grade >= 3 neurotoxicity.
Monitor patients from the start of the tarlatamab-dlle infusion for 22 to 24 hours following the next dose of tarlatamab-dlle. Grade 4 ICE score 0 Permanently ICU care. (patient is discontinue Consider unarousable and tarlatamab-dlle. mechanical unable to perform ventilation for ICE) and/or airway stupor or coma protection.
High and/or dose life-threatening corticosteroids prolonged seizure (e.g., (>5 minutes) or methylprednisolon repetitive e 1000 mg/day in clinical or divided doses IV electrical for 3 days). seizures without Consider repeat return to neuroimaging (CT baseline in or MRI) every 2-3 between and/or days if patient diffuse cerebral has persistent edema on Grade >=3 ne neuroimaging, urotoxicity. decerebrate or Treat convulsive decorticate status posturing or epilepticus per papilledema, institutional cranial nerve VI guidelines.
palsy, or Cushing's triad.
Table 5: Recommended Treatment Interruptions of Tarlatamab-dlle for the Management of Cytopenias, Infections, and Other Adverse Reactions
Adverse Reactions Severity Dosage Modification Cytopenia Grade 3 neutropenia Withhold tarlatamab-dlle until recovery to Grade <=2. Consider administration of granulocyte colony stimulating factor (G-CSF). Permanently discontinue if recovery to Grade <=2 does not occur within 3 weeks.
Cytopenia Grade 4 neutropenia Withhold tarlatamab-dlle until recovery to Grade <=2. Consider administration of G-CSF. Permanently discontinue if recovery to Grade <=2 does not occur within 1 week.
Cytopenia Recurrent Grade 4 Permanently discontinue neutropenia tarlatamab-dlle. Cytopenia Febrile neutropenia Withhold tarlatamab-dlle until neutropenia recovers to Grade <=2 and fever resolves. Cytopenia Hemoglobin <8 g/dL Withhold tarlatamab-dlle until hemoglobin is >=8 g/dL.
Cytopenia Grade 3 or 4 decreased Withhold tarlatamab-dlle platelet count until platelet count is Grade <=2 and no evidence of bleeding. Permanently discontinue if recovery to Grade <=2 does not occur within 3 weeks. Cytopenia Recurrent Grade 4 Permanently discontinue decreased platelet count tarlatamab-dlle.
Infections All Grades Withhold tarlatamab-dlle in the step-up phase in patients until infection resolves. Infections Grade 3 Withhold tarlatamab-dlle during the treatment phase until infection improves to Grade <=1. Infections Grade 4 Permanently discontinue tarlatamab-dlle.
Hepatotoxicity Grade 3 increased ALT, Withhold tarlatamab-dlle AST, bilirubin until improved to Grade <=1. Hepatotoxicity Grade 4 increased ALT, Permanently discontinue AST, or bilirubin tarlatamab-dlle Hepatotoxicity AST, ALT >3 x ULN with Permanently discontinue total bilirubin >2 x ULN tarlatamab-dlle. in the absence of alternative causes Other Adverse Reactions Grade 3 or 4 Withhold tarlatamab-dlle until recovery to Grade <=1 or baseline.
Consider permanently discontinuing if adverse reaction does not resolve within 28 days. Consider permanent discontinuation for Grade 4 events.
See Table 2 for recommendations on restarting tarlatamab-dlle after dose delays.
Guidelines for the management of neurologic toxicity are based on the Immune Effector Cell-Associated Encephalopathy (ICE) score. The manufacturer recommends that ICE assessments be performed if the patient is arousable. Assess orientation (oriented to year, month, city, hospital=4 points); naming (names 3 objects, e.g., point to clock, pen, button=3 points); following commands (e.g., "show me 2 fingers" or "close your eyes and stick out your tongue"= 1 point); writing (ability to write a standard sentence=1 point); and attention (count backwards from 100 by ten=1 point).
If patient is unarousable and unable to perform ICE assessment (Grade 4 ICANS)=0 points.
Table 3: Guidelines for Grading and Dosage Modification and Management of Cytokine Release Syndrome
CRS Grade Defining Symptoms Tarlatamab-dlle Management Dosage Modification Grade 1 Symptoms require Withhold Administer symptomatic tarlatamab-dlle symptomatic treatment only until event treatment (e.g., (e.g., fever resolves, then acetaminophen) >=100.4degrees resume for fever. without tarlatamab-dlle Consider hypotension or at the next dexamethasone 4 hypoxia).
scheduled dose. mg to 10 mg oral or IV (or equivalent). Taper steroids per standard of care guidelines.
Grade 2 Symptoms require Withhold Recommend and respond to tarlatamab-dlle hospitalization moderate until event for a minimum of intervention. resolves, then 24 hours with Fever resume cardiac telemetry >=100.4degreesF, tarlatamab-dlle and pulse hypotension at the next oximetry.
responsive to scheduled dose. Administer fluids not symptomatic requiring treatment (e.g., vasopressors acetaminophen) and/or hypoxia for fever. requiring low Administer flow nasal supplemental cannula or oxygen and IV blow-by.
fluids when indicated. Consider dexamethasone (or equiva lent) 8 mg oral or IV. Taper steroids per standard of care guidelines.
Consider tocilizumab (or equivalent) When resuming the next planned dose, monitor patients from the start of the tarlatamab-dlle infusion for 22 to 24 hours in an appropriate healthcar e setting. Grade 3 Severe symptoms Withhold In addition to defined as tarlatamab-dlle Grade 2 temperature until the event treatment: >=100.4degreesF resolves, then Recommend with hemodynamic resume intensive instability tarlatamab-dlle monitoring, e.g.,
requiring a at the next intensive care vasopressor (with scheduled dose. unit (ICU) care. or without For recurrent Administer vasopressin) Grade 3 events, dexamethasone (or and/or worsening permanently equivalent) 8 mg hypoxia or discontinue IV every 8 hours respiratory tarlatamab-dlle. up to 3 doses.
distress Taper steroids requiring high per standard of flow nasal care guidelines. cannula (>6 Vasopressor L/minute) or face support as ne mask. eded.
High flow oxygen support as needed. Recommend tocilizumab (or equivalent) Prior to the next dose, administer concomitant medications as recommended for cycle 1 day 1 and cycle 1 day 8 (see Premedication and Prophylaxis under Dosage and Administratio n). When resuming the next planned dose, monitor patients from the start of the tarlatamab-dlle infusion for 22 to 24 hours in an appropriate healthcare setting.
Grade 4 Life-threatening Permanently ICU care. Per symptoms defined discontinue Grade 3 as temperature tarlatamab-dlle. treatment.
>=100.4degreesF Recommend with hemodynamic tocilizumab (or instability equivalent) requiring multiple vasopressors (excluding vasopressin) and/or worsening hypoxia or respiratory distress despite oxygen administration requiring positive pressure.
Table 4: Guidelines for Management of Neurologic Toxicity including Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
ICANS Grade Defining Symptoms Tarlatamab-dlle Management Dosage Modifications Grade 1 ICE score 7-9 Withhold Supportive care. with no depressed tarlatamab-dlle level of until ICANS consciousness. resolves, then resume tarlatamab-dlle at the next scheduled dose.
Grade 2 ICE score 3-6 Withhold Supportive care. and/or mild tarlatamab-dlle Dexamethasone (or somnolence until ICANS equivalent) 8 to awakening to resolves, then 10 mg oral or IV. voice.
resume Taper steroids tarlatamab-dlle per standard of at the next care guidelines. scheduled dose. Monitor neurologic symptoms and consider consultation with neurologist and other specialists for further evaluation and management.
Monit or patients from the start of the tarlatamab-dlle infusion for 22 to 24 hours following the next dose of tarlatamab-dlle. Grade 3 ICE score 0-2 Withhold Recommend and/or depressed tarlatamab-dlle intensive level of until the ICANS monitoring, e.g.,
consciousness resolves, then ICU care. awakening only to resume Consider tactile stimulus tarlatamab-dlle mechanical and/or any at the next ventilation for clinical seizure scheduled dose. airway focal or If there is no protection.
generalized that improvement to Dexamethasone (or resolves rapidly Grade <=1 within equivalent) 10 mg or nonconvulsive 7 days IV every 6 hours seizures on EEG permanently or that resolve with discontinue methylprednisolon intervention tarlatamab-dlle. e (or equivalent) and/or focal or For recurrent 1 mg/kg IV every local edema on Grade 3 events, 12 hours. Taper permanently steroids per discontinue standard of car neuroimaging.
tarlatamab-dlle. e guidelines. Consider repeat neuroimaging (e.g., computed tomography (CT) or magnetic resonance imaging (MRI)) every 2-3 days if patient has persistent Grade >= 3 neurotoxicity.
Monitor patients from the start of the tarlatamab-dlle infusion for 22 to 24 hours following the next dose of tarlatamab-dlle. Grade 4 ICE score 0 Permanently ICU care. (patient is discontinue Consider unarousable and tarlatamab-dlle. mechanical unable to perform ventilation for ICE) and/or airway stupor or coma protection.
High and/or dose life-threatening corticosteroids prolonged seizure (e.g., (>5 minutes) or methylprednisolon repetitive e 1000 mg/day in clinical or divided doses IV electrical for 3 days). seizures without Consider repeat return to neuroimaging (CT baseline in or MRI) every 2-3 between and/or days if patient diffuse cerebral has persistent edema on Grade >=3 ne neuroimaging, urotoxicity. decerebrate or Treat convulsive decorticate status posturing or epilepticus per papilledema, institutional cranial nerve VI guidelines.
palsy, or Cushing's triad.
Table 5: Recommended Treatment Interruptions of Tarlatamab-dlle for the Management of Cytopenias, Infections, and Other Adverse Reactions
Adverse Reactions Severity Dosage Modification Cytopenia Grade 3 neutropenia Withhold tarlatamab-dlle until recovery to Grade <=2. Consider administration of granulocyte colony stimulating factor (G-CSF). Permanently discontinue if recovery to Grade <=2 does not occur within 3 weeks.
Cytopenia Grade 4 neutropenia Withhold tarlatamab-dlle until recovery to Grade <=2. Consider administration of G-CSF. Permanently discontinue if recovery to Grade <=2 does not occur within 1 week.
Cytopenia Recurrent Grade 4 Permanently discontinue neutropenia tarlatamab-dlle. Cytopenia Febrile neutropenia Withhold tarlatamab-dlle until neutropenia recovers to Grade <=2 and fever resolves. Cytopenia Hemoglobin <8 g/dL Withhold tarlatamab-dlle until hemoglobin is >=8 g/dL.
Cytopenia Grade 3 or 4 decreased Withhold tarlatamab-dlle platelet count until platelet count is Grade <=2 and no evidence of bleeding. Permanently discontinue if recovery to Grade <=2 does not occur within 3 weeks. Cytopenia Recurrent Grade 4 Permanently discontinue decreased platelet count tarlatamab-dlle.
Infections All Grades Withhold tarlatamab-dlle in the step-up phase in patients until infection resolves. Infections Grade 3 Withhold tarlatamab-dlle during the treatment phase until infection improves to Grade <=1. Infections Grade 4 Permanently discontinue tarlatamab-dlle.
Hepatotoxicity Grade 3 increased ALT, Withhold tarlatamab-dlle AST, bilirubin until improved to Grade <=1. Hepatotoxicity Grade 4 increased ALT, Permanently discontinue AST, or bilirubin tarlatamab-dlle Hepatotoxicity AST, ALT >3 x ULN with Permanently discontinue total bilirubin >2 x ULN tarlatamab-dlle. in the absence of alternative causes Other Adverse Reactions Grade 3 or 4 Withhold tarlatamab-dlle until recovery to Grade <=1 or baseline.
Consider permanently discontinuing if adverse reaction does not resolve within 28 days. Consider permanent discontinuation for Grade 4 events.
Tarlatamab-dlle is administered via IV infusion only. IV bags composed of ethyl vinyl acetate (EVA), polyolefin, and polyvinyl chloride (PVC) have been shown to be compatible with tarlatamab-dlle at the specified administration conditions. IV line and catheter materials composed of polyolefin, PVC, and polyurethane have been shown to be compatible with tarlatamab-dlle at the specified administration conditions.
The use of a closed system transfer device (CSTD) is not recommended due to potential wrong dose medication error risk. Compatibility testing of vial adaptor CSTDs with tarlatamab-dlle has not been conducted. The IV catheter for concomitant medication administration can be used to administer the tarlatamab-dlle infusion.
To ensure patency, flush the IV catheter over 3 to 5 minutes using 0.9% sodium chloride injection. Initiate tarlatamab-dlle therapy according to the step-up dose and schedule in Table 1 to reduce the incidence and severity of cytokine release syndrome (CRS).
After step-up dose and schedule on cycle 1 day 1, administer tarlatamab-dlle every 2 weeks until disease progression or unacceptable toxicity. Store tarlatamab-dlle and IV solution stabilizer (IVSS) vials refrigerated at 2-8degreesC in the original carton to protect from light until time of use. Do not freeze. Tarlatamab-dlle and IVSS vials may be kept at room temperature between 20-25degreesC for up to 24 hours in the original carton to protect from light.
The use of a closed system transfer device (CSTD) is not recommended due to potential wrong dose medication error risk. Compatibility testing of vial adaptor CSTDs with tarlatamab-dlle has not been conducted. The IV catheter for concomitant medication administration can be used to administer the tarlatamab-dlle infusion.
To ensure patency, flush the IV catheter over 3 to 5 minutes using 0.9% sodium chloride injection. Initiate tarlatamab-dlle therapy according to the step-up dose and schedule in Table 1 to reduce the incidence and severity of cytokine release syndrome (CRS).
After step-up dose and schedule on cycle 1 day 1, administer tarlatamab-dlle every 2 weeks until disease progression or unacceptable toxicity. Store tarlatamab-dlle and IV solution stabilizer (IVSS) vials refrigerated at 2-8degreesC in the original carton to protect from light until time of use. Do not freeze. Tarlatamab-dlle and IVSS vials may be kept at room temperature between 20-25degreesC for up to 24 hours in the original carton to protect from light.
| DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
|---|---|---|
| IMDELLTRA 1 MG VIAL | Maintenance | Adults infuse 1 mg over 1 hour(s) by intravenous route on day 1 of treatment (cycle 1) |
| IMDELLTRA 10 MG VIAL | Maintenance | Adults infuse 10 mg over 1 hour(s) by intravenous route on days 1 and 15 of treatment (cycle 2 and beyond) |
No generic dosing information available.
The following drug interaction information is available for IMDELLTRA (tarlatamab-dlle):
There are 4 contraindications.
These drug combinations generally should not be dispensed or administered to the same patient. A manufacturer label warning that indicates the contraindication warrants inclusion of a drug combination in this category, regardless of clinical evidence or lack of clinical evidence to support the contraindication.
| Drug Interaction | Drug Names |
|---|---|
| Efalizumab; Natalizumab/Immunosuppressives; Immunomodulators SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient. MECHANISM OF ACTION: Natalizumab,(1-3) efalizumab,(4) immunosuppressives, and immunomodulators all suppress the immune system. CLINICAL EFFECTS: Concurrent use of natalizumab(1-3) or efalizumab(4) with immunosuppressives or immunomodulators may result in an increased risk of infections, including progressive multifocal leukoencephalopathy (PML), an opportunistic infection caused by the JC virus (JCV). PREDISPOSING FACTORS: Previous JCV infection, longer duration of natalizumab treatment - especially if greater than 2 years, and prior or concomitant treatment with immunosuppressant medication are all independent risk factors which increase the risk for PML.(1,5) The FDA has estimated PML incidence stratified by risk factors: If anti-JCV antibody positive, no prior immunosuppressant use and natalizumab treatment less than 25 months, incidence <1/1,000. If anti-JCV antibody positive, history of prior immunosuppressant use and natalizumab treatment less than 25 months, incidence 2/1,000 If anti-JCV antibody positive, no prior immunosuppressant use and natalizumab treatment 25-48 months, incidence 4/1,000 If anti-JCV antibody positive, history of prior immunosuppressant use and natalizumab treatment 25-48 months, incidence 11/1,000. PATIENT MANAGEMENT: The US manufacturer of natalizumab states patients with Crohn's disease should not receive concurrent immunosuppressants, with the exception of limited overlap of corticosteroids, due to the increased risk for PML. For new natalizumab patients currently receiving chronic oral corticosteroids for Crohn's Disease, begin corticosteroid taper when therapeutic response to natalizumab has occurred. If corticosteroids cannot be discontinued within six months of starting natalizumab, discontinue natalizumab.(3) The US manufacturer of natalizumab states that natalizumab should not ordinarily be used in multiple sclerosis patients receiving immunosuppressants or immunomodulators due to the increased risk for PML. Immunosuppressives include, but are not limited to azathioprine, cyclophosphamide, cyclosporine, mercaptopurine, methotrexate, mitoxantrone, mycophenolate, and corticosteroids.(3,6) The UK manufacturer of natalizumab states that concurrent use with immunosuppressives or antineoplastic agents is contraindicated.(1) The Canadian manufacturer of natalizumab states that natalizumab should not be used with immunosuppressive or immunomodulatory agents.(2) The US manufacturer of certolizumab states that concurrent therapy with natalizumab is not recommended.(7) DISCUSSION: Progressive multifocal leukoencephalopathy has been reported in patients receiving concurrent natalizumab were recently or concomitantly taking immunomodulators or immunosuppressants.(1-5,8,9) In a retrospective cohort study of multiple sclerosis patients newly initiated on a disease-modifying therapy, use of high-efficacy agents (alemtuzumab, natalizumab, or ocrelizumab) resulted in the same risk of overall infections as moderate-efficacy agents, but there was an elevated risk of serious infections (adjusted hazard ratio [aHR] = 1.24, 95% confidence interval (CI) = 1.06-1.44) and UTIs (aHR = 1.21, 95% CI = 1.14-1.30).(10) |
TYRUKO, TYSABRI |
| Live Vaccines; Live BCG/Selected Immunosuppressive Agents SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient. MECHANISM OF ACTION: A variety of disease modifying agents suppress the immune system. Immunocompromised patients may be at increased risk for uninhibited replication after administration of live, attenuated vaccines or intravesicular BCG. Immune response to vaccines may be decreased during periods of immunocompromise.(1) CLINICAL EFFECTS: The expected serum antibody response may not be obtained and/or the vaccine may result in illness.(1) After instillation of intravesicular BCG, immunosuppression may interfere with local immune response, or increase the severity of mycobacterial infection following inadvertent systemic exposure.(2) PREDISPOSING FACTORS: Immunosuppressive diseases (e.g. hematologic malignancies, HIV disease), treatments (e.g. radiation) and drugs may all increase the magnitude of immunodeficiency. PATIENT MANAGEMENT: The Centers for Disease Control(CDC) Advisory Committee on Immunization Practices (ACIP) states that live-virus and live, attenuated vaccines should not be administered to patients who are immunocompromised. The magnitude of immunocompromise and associated risks should be determined by a physician.(1) For patients scheduled to receive chemotherapy, vaccination should ideally precede the initiation of chemotherapy by 14 days. Patients vaccinated while on immunosuppressive therapy or in the 2 weeks prior to starting therapy should be considered unimmunized and should be revaccinated at least 3 months after discontinuation of therapy.(1) Patients who receive anti-B cell therapies should not receive live vaccines for at least 6 months after such therapies due to a prolonged duration of immunosuppression. An exception is the Zoster vaccine, which can be given at least 1 month after receipt of anti-B cell therapies.(1) The US manufacturer of abatacept states live vaccines should not be given during or for up to 3 months after discontinuation of abatacept.(2) The US manufacturer of live BCG for intravesicular treatment of bladder cancer states use is contraindicated in immunosuppressed patients.(3) The US manufacturer of daclizumab states live vaccines are not recommended during and for up to 4 months after discontinuation of treatment.(4) The US manufacturer of guselkumab states that live vaccines should be avoided during treatment with guselkumab.(5) The US manufacturer of inebilizumab-cdon states that live vaccines are not recommended during treatment and after discontinuation until B-cell repletion. Administer all live vaccinations at least 4 weeks prior to initiation of inebilizumab-cdon.(6) The US manufacturer of ocrelizumab states that live vaccines are not recommended during treatment and until B-cell repletion occurs after discontinuation of therapy. Administer all live vaccines at least 4 weeks prior to initiation of ocrelizumab.(7) The US manufacturer of ozanimod states that live vaccines should be avoided during and for up to 3 months after discontinuation of ozanimod.(8) The US manufacturer of siponimod states that live vaccines are not recommended during treatment and for up to 4 weeks after discontinuation of treatment.(9) The US manufacturer of ustekinumab states BCG vaccines should not be given in the year prior to, during, or the year after ustekinumab therapy.(10) The US manufacturer of satralizumab-mwge states that live vaccines are not recommended during treatment and should be administered at least four weeks prior to initiation of satralizumab-mwge.(11) The US manufacturer of ublituximab-xiiy states that live vaccines are not recommended during treatment and until B-cell recovery. Live vaccines should be administered at least 4 weeks prior to initiation of ublituximab-xiiy.(12) The US manufacturer of etrasimod states that live vaccines should be avoided during and for 5 weeks after treatment. Live vaccines should be administered at least 4 weeks prior to initiation of etrasimod.(13) The US manufacturer of emapalumab-lzsg states that live vaccines should not be administered to patients receiving emapalumab-lzsg and for at least 4 weeks after the last dose of emapalumab-lzsg. The safety of immunization with live vaccines during or following emapalumab-lzsg therapy has not been studied.(14) The US manufacturer of sibeprenlimab-szsi states live vaccines should not be given within 30 days prior to initiation or during treatment with sibeprenlimab-szsi.(15) DISCUSSION: Killed or inactivated vaccines do not pose a danger to immunocompromised patients.(1) Patients with a history of leukemia who are in remission and have not received chemotherapy for at least 3 months are not considered to be immunocompromised.(1) |
ACAM2000 (NATIONAL STOCKPILE), ADENOVIRUS TYPE 4, ADENOVIRUS TYPE 4 AND TYPE 7, ADENOVIRUS TYPE 7, BCG (TICE STRAIN), BCG VACCINE (TICE STRAIN), DENGVAXIA, ERVEBO (NATIONAL STOCKPILE), FLUMIST 2025-2026, FLUMIST HOME 2025-2026, M-M-R II VACCINE, PRIORIX, PROQUAD, ROTARIX, ROTATEQ, STAMARIL, VARIVAX VACCINE, VAXCHORA ACTIVE COMPONENT, VAXCHORA VACCINE, VIVOTIF, YF-VAX |
| Talimogene laherparepvec/Selected Immunosuppressants SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient. MECHANISM OF ACTION: Talimogene laherparepvec is a live, attenuated herpes simplex virus.(1) CLINICAL EFFECTS: Concurrent use of talimogene laherparepvec in patients receiving immunosuppressive therapy may cause a life-threatening disseminated herpetic infection.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Talimogene laherparepvec is contraindicated in immunosuppressed patients.(1) The magnitude of immunocompromise and associated risks due to immunosuppressant drugs should be determined by a physician. DISCUSSION: Concurrent use of talimogene laherparepvec in patients receiving immunosuppressive therapy may cause a life-threatening disseminated herpetic infection.(1) |
IMLYGIC |
| Nadofaragene Firadenovec/Selected Immunosuppressants SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient. MECHANISM OF ACTION: Nadofaragene firadenovec may contain low levels of replication-competent adenovirus.(1) CLINICAL EFFECTS: Concurrent use of nadofaragene firadenovec in patients receiving immunosuppressive therapy may cause disseminated adenovirus infection.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Individuals who are immunosuppressed or immune-deficient should not receive nadofaragene firadenovec.(1) DISCUSSION: Nadofaragene firadenovec is a non-replicating adenoviral vector-based gene therapy but may contain low levels of replication-competent adenovirus. Immunocompromised persons, including those receiving immunosuppressant therapy, may be at risk for disseminated adenovirus infection.(1) |
ADSTILADRIN |
There are 19 severe interactions.
These drug interactions can produce serious consequences in most patients. Actions required for severe interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration scheduling, and providing additional patient monitoring. Review the full interaction monograph for more information.
| Drug Interaction | Drug Names |
|---|---|
| Deferiprone/Selected Myelosuppressive Agents SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Concurrent use of deferiprone with other drugs known to be associated with neutropenia or agranulocytosis may increase the frequency or risk for severe toxicity.(1) CLINICAL EFFECTS: Concurrent use of deferiprone and myelosuppressive agents may result in severe neutropenia or agranulocytosis, which may be fatal. PREDISPOSING FACTORS: Agranulocytosis may be less common in patients receiving deferiprone for thalassemia, and more common in patients treated for other systemic iron overload conditions (e.g. myelodysplastic syndromes, sickle cell disease).(2,3) Inadequate monitoring appears to increase the risk for severe outcomes. Manufacturer post market surveillance found that in all fatal cases of agranulocytosis reported between 1999 and 2005, data on weekly white blood count (WBC) monitoring was missing. In three fatal cases, deferiprone was continued for two to seven days after the detection of neutropenia or agranulocytosis.(2) PATIENT MANAGEMENT: If possible, discontinue one of the drugs associated with risk for neutropenia or agranulocytosis. If alternative therapy is not available, documentation and adherence to the deferiprone monitoring protocol is essential. Baseline absolute neutrophil count (ANC) must be at least 1,500/uL prior to starting deferiprone. Monitor ANC weekly during therapy. If infection develops, interrupt deferiprone therapy and monitor ANC more frequently. If ANC is less than 1,500/uL but greater than 500/uL, discontinue deferiprone and any other drugs possibly associated with neutropenia. Initiate ANC and platelet counts daily until recovery (i.e. ANC at least 1,500/uL). If ANC is less than 500/uL, discontinue deferiprone, evaluate patient and hospitalize if appropriate. Do not resume deferiprone unless potential benefits outweigh potential risks.(1) DISCUSSION: Drugs linked to this monograph have an FDA Boxed Warning for risk of neutropenia, agranulocytosis, or pancytopenia, or have > 5% risk for neutropenia and/or warnings describing risk for myelosuppression in manufacturer prescribing information.(1-25) In pooled clinical studies submitted to the FDA, 6.1% of deferiprone patients met criteria for neutropenia and 1.7% of patients developed agranulocytosis.(1) The time to onset of agranulocytosis was highly variable with a range of 65 days to 9.2 years (median, 161 days).(3) |
DEFERIPRONE, DEFERIPRONE (3 TIMES A DAY), FERRIPROX, FERRIPROX (2 TIMES A DAY), FERRIPROX (3 TIMES A DAY) |
| Tofacitinib/Immunosuppressives; Immunomodulators SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Concurrent use of tofacitinib and azathioprine, other biologic disease-modifying antirheumatic drugs (DMARDs), or potent immunosuppressants may result in additive or synergistic effects on the immune system.(1) CLINICAL EFFECTS: Concurrent use of tofacitinib and azathioprine, other biologic DMARDs, or potent immunosuppressants use may increase the risk of serious infections.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Tofacitinib should not be used concurrently with azathioprine, other biologic DMARDs, or cyclosporine.(1) Patient should be monitored for decreases in lymphocytes and neutrophils. Therapy should be adjusted based on the indication. - For all indications: If absolute neutrophil count (ANC) or lymphocyte count is less than 500 cells/mm3, discontinue tofacitinib. - For rheumatoid arthritis or psoriatic arthritis and absolute neutrophil count (ANC) 500 to 1000 cells/mm3: interrupt dosing. When ANC is greater than 1000 cells/mm3, resume Xeljanz 5 mg twice daily or Xeljanz XR 11 mg once daily. - For ulcerative colitis and ANC 500 to 1000 cells/mm3: -If taking Xeljanz 10 mg twice daily, decrease to 5 mg twice daily. When ANC is greater than 1000 cells/mm3, increase to 10 mg twice daily based on clinical response. -If taking Xeljanz 5 mg twice daily, interrupt dosing. When ANC is greater than 1000 cells/mm3, resume 5 mg twice daily. -If taking Xeljanz XR 22 mg once daily, decrease to 11 mg once daily. When ANC is greater than 1000 cells/mm3, increase to 22 mg once daily based on clinical response. -If taking Xeljanz XR 11 mg once daily, interrupt dosing. When ANC is greater than 1000 cells/mm3, resume 11 mg once daily. - For polyarticular course juvenile idiopathic arthritis (pcJIA) and ANC 500 to 1000 cells/mm3: interrupt dosing until ANC is greater than 1000 cells/mm3.(1) DISCUSSION: Concurrent use of tofacitinib and azathioprine, other biologic DMARDs, or potent immunosuppressants may increase the risk of infection.(1) Serious infections due to bacterial, mycobacterial, invasive fungal, viral, or other opportunistic pathogens have been reported in patients receiving tofacitinib. Some patients presented with disseminated disease and were often taking concomitant immunomodulating agents. In the ulcerative colitis population, a greater risk of serious infections was seen with a higher tofacitinib dose. In 7 placebo-controlled rheumatoid arthritis trials (0-3 months exposure), the overall frequency of infections was 20% in the tofacitinib 5 mg twice daily group and 22% in the tofacitinib 10 mg twice daily group compared to 18% in the placebo group. Serious infections were reported in 11 patients (1.7 events per 100 patient-years) with a rate difference between treatment groups of 1.1 (-0.4, 2.5) events per 100 patient-years for both tofacitinib 5 mg twice daily and 10 mg twice daily. During 0-12 months exposure, serious infections were reported in 34 patients (2.7 events per 100 patient years) in the tofacitinib 5 mg twice daily group and 33 patients (2.7 events per 100 patient years) in the tofacitinib 10 mg twice daily group.(1) |
TOFACITINIB CITRATE, XELJANZ, XELJANZ XR |
| Clozapine/Selected Myelosuppressive Agents SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Clozapine and other myelosuppressive agents may be associated with neutropenia or agranulocytosis.(2) CLINICAL EFFECTS: Moderate neutropenia, even if due to combination therapy, may require abrupt discontinuation of clozapine resulting in decompensation of the patient's psychiatric disorder (e.g. schizophrenia). The disease treated by the myelosuppressive agent may be compromised if myelosuppression requires dose reduction, delay, or discontinuation of the myelosuppressive agent. Undetected severe neutropenia or agranulocytosis may be fatal. PREDISPOSING FACTORS: Low white blood counts prior to initiation of the myelosuppressive agent may increase risk for clinically significant neutropenia. PATIENT MANAGEMENT: If a patient stabilized on clozapine therapy requires treatment with a myelosuppressive agent, the clozapine prescriber should consult with prescriber of the myelosuppressive agent (e.g. oncologist) to discuss treatment and monitoring options.(2) More frequent absolute neutrophil count (ANC) monitoring or treatment alternatives secondary to neutropenic episodes may need to be considered. The U.S. Food and Drug Administration (FDA) recommends that prescribers monitor patients' ANC according to the monitoring frequencies described in the prescribing information. Severe neutropenia remains a serious, potentially fatal risk that is greatest in the first several months of clozapine treatment. ANC monitoring can help identify neutropenia early to allow for timely intervention.(1-2) Australia, Canada, and U.K.: Clozapine is only available through a restricted distribution system which requires documentation of the ANC prior to dispensing. For most clozapine patients, clozapine treatment must be interrupted for a suspected clozapine-induced ANC < 1000 cells/microliter. For patients with benign ethnic neutropenia (BEN), treatment must be interrupted for suspected clozapine-induced neutropenia < 500 cells/microliter.(2) DISCUSSION: Concurrent use of clozapine and selected myelosuppressive agents may require more frequent ANC monitoring or consideration of treatment alternatives secondary to neutropenic episodes. Agents linked to this interaction generally have > 5% risk for neutropenia and/or warnings describing risk for myelosuppression in manufacturer prescribing information.(3-26) |
CLOZAPINE, CLOZAPINE ODT, CLOZARIL, VERSACLOZ |
| Selected Multiple Sclerosis Agents/Immunosuppressants; Immunomodulators SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Ocrelizumab or ofatumumab in combination with immunosuppressives and immune-modulators all suppress the immune system.(1,2) CLINICAL EFFECTS: Concurrent use of ocrelizumab or ofatumumab with immunosuppressive or immune-modulating agents may result in an increased risk of serious infections, such as disseminated herpetic infection or progressive multifocal leukoencephalopathy (PML), an opportunistic infection caused by the JC virus (JCV).(1,2) PREDISPOSING FACTORS: Incomplete washout of previously prescribed immunosuppressive or immune-modulating medications. PATIENT MANAGEMENT: The ocrelizumab US prescribing information states: - Ocrelizumab and other immune-modulating or immunosuppressive therapies, (including immunosuppressant doses of corticosteroids) are expected to increase the risk of immunosuppression, and the risk of additive immune system effects must be considered if these therapies are coadministered with ocrelizumab. When switching from drugs with prolonged immune effects, such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone, the duration and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects when initiating ocrelizumab.(1) The ofatumumab US prescribing information states: - Ofatumumab and other immunosuppressive therapies (including systemic corticosteroids) may have the potential for increased immunosuppressive effects and increase the risk of infection. When switching between therapies, the duration and mechanism of action of each therapy should be considered due to the potential for additive immunosuppressive effects. Ofatumumab for MS therapy has not been studied in combination with other MS agents that suppress the immune system.(2) DISCUSSION: Fatal disseminated herpes zoster and herpes simplex infections and cases of progressive multifocal leukoencephalopathy (PML) have been reported in patients who previously received immunomodulators or immunosuppressants.(1,2) In a retrospective cohort study of multiple sclerosis patients newly initiated on a disease-modifying therapy, use of high-efficacy agents (alemtuzumab, natalizumab, or ocrelizumab) resulted in the same risk of overall infections as moderate-efficacy agents, but there was an elevated risk of serious infections (adjusted hazard ratio [aHR] = 1.24, 95% confidence interval (CI) = 1.06-1.44) and UTIs (aHR = 1.21, 95% CI = 1.14-1.30).(3) |
KESIMPTA PEN, OCREVUS, OCREVUS ZUNOVO |
| Upadacitinib/Immunosuppressives; Immunomodulators SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Upadacitinib, immunosuppressives, and immunomodulators all suppress the immune system. CLINICAL EFFECTS: Concurrent use of upadacitinib with immunosuppressives or immunomodulators may result in an increased risk of serious infections. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: The US manufacturer of upadacitinib states that concurrent use of upadacitinib with immunosuppressives or immunomodulators is not recommended. DISCUSSION: Serious infections have been reported in patients receiving upadacitinib. Reported infections included pneumonia, cellulitis, tuberculosis, multidermatomal herpes zoster, oral/esophageal candidiasis, cryptococcosis. Reports of viral reactivation, including herpes virus reactivation and hepatitis B reactivation, were reported in clinical studies with upadacitinib.(1) |
RINVOQ, RINVOQ LQ |
| Inebilizumab/Immunosuppressives; Immunomodulators SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Inebilizumab, immunosuppressives, and immunomodulators all suppress the immune system.(1) CLINICAL EFFECTS: Concurrent use of inebilizumab with immunosuppressive or immunomodulating agents may result in myelosuppression including neutropenia resulting in an increased risk for serious infections.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: The US manufacturer of inebilizumab states that the concurrent use of inebilizumab with immunosuppressive agents, including systemic corticosteroids, may increase the risk of infection. If concurrent therapy is warranted, consider the risk of additive immune suppression and monitor based on prescribing information for both agents.(1) DISCUSSION: Inebilizumab has not been studied in combination with other immunosuppressants. If concurrent therapy is warranted, consider the potential for increased immunosuppressive risks from both agents. The most common infections reported by inebilizumab treated patients in the randomized and open-label clinical trial periods included urinary tract infections (20%), nasopharyngitis (13%), upper respiratory tract infections (8%), and influenza (7%). Although there been no cases of Hepatitis B virus reactivation or progressive multifocal leukoencephalopathy reported in patients taking inebilizumab, these infections have been observed in patients taking other B-cell-depleting antibodies.(1) |
UPLIZNA |
| Baricitinib/Immunosuppressives; Immunomodulators SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Concurrent use of baricitinib with other biologic disease-modifying antirheumatic drugs (DMARDs) or potent immunosuppressants such as azathioprine or cyclosporine may result in additive or synergistic effects on the immune system. CLINICAL EFFECTS: Concurrent use of baricitinib with other biologic DMARDs or potent immunosuppressants such as azathioprine or cyclosporine may increase the risk of serious infections.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: The US manufacturer of baricitinib states that concurrent use of baricitinib with biologic DMARDs or potent immunosuppressants is not recommended.(1) DISCUSSION: Most patients who developed serious infections while being treated with baricitinib were on concomitant immunosuppressants like methotrexate and corticosteroids. The combination of baricitinib with other biologic DMARDs has not been studied.(1) |
OLUMIANT |
| Leflunomide; Teriflunomide/Selected Immunosuppressants SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Concurrent use of leflunomide or teriflunomide and potent immunosuppressants may result in additive or synergistic effects on the immune system.(1,2) Leflunomide is a prodrug and is converted to its active metabolite teriflunomide.(1) CLINICAL EFFECTS: Concurrent use of leflunomide or teriflunomide with immunosuppressants may result in an increased risk of serious infections, including opportunistic infections, especially Pneumocystis jiroveci pneumonia, tuberculosis (including extra-pulmonary tuberculosis), and aspergillosis. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: If leflunomide or teriflunomide is used concurrently with immunosuppressive agents, chronic CBC monitoring should be performed more frequently, every month instead of every 6 to 8 weeks. If bone marrow suppression or a serious infection occurs, leflunomide or teriflunomide should be stopped and rapid drug elimination procedure should be performed.(1,2) DISCUSSION: Pancytopenia, agranulocytosis and thrombocytopenia have been reported in patients receiving leflunomide or teriflunomide alone, but most frequently in patients taking concurrent immunosuppressants.(1,2) Severe and potentially fatal infections, including sepsis, have been reported in patients receiving leflunomide or teriflunomide, especially Pneumocystis jiroveci pneumonia and aspergillosis. Tuberculosis has also been reported.(1,2) |
ARAVA, AUBAGIO, LEFLUNICLO, LEFLUNOMIDE, TERIFLUNOMIDE |
| Ponesimod/Immunosuppressives; Immunomodulators SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Ponesimod in combination with immunosuppressives and immune-modulators all suppress the immune system.(1) CLINICAL EFFECTS: Concurrent use of ponesimod with immunosuppressive or immune-modulating agents may result in an increased risk of serious infections, such as disseminated herpetic infection, cryptococcal infection, or progressive multifocal leukoencephalopathy (PML), an opportunistic infection caused by the JC virus (JCV).(1) PREDISPOSING FACTORS: Incomplete washout of previously prescribed immunosuppressive or immune-modulating medications. PATIENT MANAGEMENT: The ponesimod US prescribing information states ponesimod has not been studied in combination with anti-neoplastic, immune-modulating, or immunosuppressive therapies. Caution should be used during concomitant administration because of the risk of additive immune effects during therapy and in the weeks following administration. When switching from drugs with prolonged immune effects, the half-life and mode of action of these drugs must be considered in order to avoid unintended additive immunosuppressive effects. Initiating treatment with ponesimod after alemtuzumab is not recommended. However, ponesimod can generally be started immediately after discontinuation of beta interferon or glatiramer acetate.(1) DISCUSSION: Fatal disseminated herpes zoster and herpes simplex infections, cryptococcal meningitis, disseminated cryptococcal infections, and cases of progressive multifocal leukoencephalopathy (PML) have been reported in patients who previously received immunomodulators or immunosuppressants.(1) |
PONVORY |
| Sodium Iodide I 131/Myelosuppressives; Immunomodulators SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Sodium iodide I 131 can cause depression of the hematopoetic system. Myelosuppressives and immunomodulators also suppress the immune system.(1) CLINICAL EFFECTS: Concurrent use of sodium iodide I 131 with agents that cause bone marrow depression, including myelosuppressives or immunomodulators, may result in an enhanced risk of hematologic disorders, including anemia, blood dyscrasias, bone marrow depression, leukopenia, and thrombocytopenia. Bone marrow depression may increase the risk of serious infections and bleeding.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: The US manufacturer of sodium iodide I 131 states that concurrent use with bone marrow depressants may enhance the depression of the hematopoetic system caused by large doses of sodium iodide I 131.(1) Sodium iodide I 131 causes a dose-dependent bone marrow suppression, including neutropenia or thrombocytopenia, in the 3 to 5 weeks following administration. Patients may be at increased risk of infections or bleeding during this time. Monitor complete blood counts within one month of therapy. If results indicate leukopenia or thrombocytopenia, dosimetry should be used to determine a safe sodium iodide I 131 activity.(1) DISCUSSION: Hematologic disorders including death have been reported with sodium iodide I 131. The most common hematologic disorders reported include anemia, blood dyscrasias, bone marrow depression, leukopenia, and thrombocytopenia.(1) |
HICON, SODIUM IODIDE I-131 |
| Fingolimod/Immunosuppressives; Immunomodulators SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Fingolimod in combination with immunosuppressives and immune-modulators all suppress the immune system.(1-3) CLINICAL EFFECTS: Concurrent use of fingolimod with immunosuppressive or immune-modulating agents may result in an increased risk of serious infections, such as disseminated herpetic infection or progressive multifocal leukoencephalopathy (PML), an opportunistic infection caused by the JC virus (JCV).(1-3) PREDISPOSING FACTORS: Incomplete washout of previously prescribed immunosuppressive or immune-modulating medications. PATIENT MANAGEMENT: Recommendations for fingolimod regarding this interaction differ between regulatory approving agencies. The fingolimod US prescribing information states: - Antineoplastic, immune-modulating, or immunosuppressive therapies, (including corticosteroids) are expected to increase the risk of immunosuppression, and the risk of additive immune system effects must be considered if these therapies are coadministered with fingolimod. When switching from drugs with prolonged immune effects, such as natalizumab, teriflunomide or mitoxantrone, the duration and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects when initiating fingolimod.(1) The fingolimod Canadian prescribing information states: - Concurrent use with immunosuppressive or immunomodulatory agents is contraindicated due to the risk of additive immune system effects. However, co-administration of a short course of corticosteroids (up to 5 days) did not increase the overall rate of infection in patients participating Phase III clinical trials.(2) The fingolimod UK specific product characteristics states: - Fingolimod is contraindicated in patients currently receiving immunosuppressive therapies or those immunocompromised by prior therapies. When switching patients from another disease modifying therapy to Gilenya, the half-life and mode of action of the other therapy must be considered in order to avoid an additive immune effect whilst at the same time minimizing the risk of disease activation.(3) DISCUSSION: Fatal disseminated herpes zoster and herpes simplex infections and cases of progressive multifocal leukoencephalopathy (PML) have been reported in patients who previously received immunomodulators or immunosuppressants.(1-3) |
FINGOLIMOD, GILENYA, TASCENSO ODT |
| Ozanimod/Immunosuppressives; Immunomodulators SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Ozanimod in combination with immunosuppressives and immune-modulators all suppress the immune system.(1) CLINICAL EFFECTS: Concurrent use of ozanimod with immunosuppressive or immune-modulating agents may result in an increased risk of serious infections, such as disseminated herpetic infection or progressive multifocal leukoencephalopathy (PML), an opportunistic infection caused by the JC virus (JCV).(1) PREDISPOSING FACTORS: Incomplete washout of previously prescribed immunosuppressive or immune-modulating medications. PATIENT MANAGEMENT: The ozanimod US prescribing information state this information regarding this interaction: -Ozanimod has not been studied in combination with anti-neoplastic, immune-modulating, or immunosuppressive therapies. Caution should be used during concomitant administration because of the risk of additive immune effects during therapy and in the week following administration. When switching from drugs with prolonged immune effects, the half-life and mode of action of these drugs must be considered in order to avoid unintended additive immunosuppressive effects. Initiating treatment with ozanimod after alemtuzumab is not recommended. However, ozanimod can generally be started immediately after discontinuation of beta interferon or glatiramer acetate.(1) DISCUSSION: Fatal disseminated herpes zoster and herpes simplex infections and cases of progressive multifocal leukoencephalopathy (PML) have been reported in patients who previously received immunomodulators or immunosuppressants.(1) |
ZEPOSIA |
| Siponimod/Immunosuppressives; Immunomodulators SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Siponimod in combination with immunosuppressives and immune-modulators all suppress the immune system.(1) CLINICAL EFFECTS: Concurrent use of siponimod with immunosuppressive or immune-modulating agents may result in an increased risk of serious infections, such as disseminated herpetic infection or progressive multifocal leukoencephalopathy (PML), an opportunistic infection caused by the JC virus (JCV).(1) PREDISPOSING FACTORS: Incomplete washout of previously prescribed immunosuppressive or immune-modulating medications. PATIENT MANAGEMENT: The siponimod US prescribing information state this information regarding this interaction: -Siponimod has not been studied in combination with anti-neoplastic, immune-modulating, or immunosuppressive therapies. Caution should be used during concomitant administration because of the risk of additive immune effects during therapy and in the week following administration. When switching from drugs with prolonged immune effects, the half-life and mode of action of these drugs must be considered in order to avoid unintended additive immunosuppressive effects. Initiating treatment with siponimod after alemtuzumab is not recommended. However, siponimod can generally be started immediately after discontinuation of beta interferon or glatiramer acetate.(1) DISCUSSION: Fatal disseminated herpes zoster and herpes simplex infections and cases of progressive multifocal leukoencephalopathy (PML) have been reported in patients who previously received immunomodulators or immunosuppressants.(1) |
MAYZENT |
| Cladribine Oral/Immunosuppressives; Immunomodulators SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Cladribine in combination with immunosuppressives and immune-modulators all suppress the immune system.(1-2) CLINICAL EFFECTS: Concurrent use of cladribine with immunosuppressive or immune-modulating agents may result in an increased risk of serious infections, such as disseminated herpetic infection or progressive multifocal leukoencephalopathy (PML), an opportunistic infection caused by the JC virus (JCV).(1-2) PREDISPOSING FACTORS: Incomplete washout of previously prescribed immunosuppressive or immune-modulating medications. PATIENT MANAGEMENT: Recommendations for cladribine regarding this interaction differ between regulatory approving agencies. The cladribine US prescribing information states: -Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. Acute short-term therapy with corticosteroids can be administered. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, the mode of action, and duration of effect of the other drugs prior to initiation of cladribine.(1) The cladribine Canadian prescribing information states: -Use of cladribine in immunocompromised patients is contraindicated because of a risk of additive effects on the immune system. Acute short-term therapy with corticosteroids can be administered during cladribine treatment.(2) DISCUSSION: Fatal disseminated herpes zoster and herpes simplex infections and cases of progressive multifocal leukoencephalopathy (PML) have been reported in patients who previously received immunomodulators or immunosuppressants.(1-2) |
CLADRIBINE, MAVENCLAD |
| Anifrolumab/Biologic Therapies SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Concurrent use of anifrolumab with other biologic therapies may result in additive or synergistic effects on the immune system.(1) CLINICAL EFFECTS: Concurrent use of anifrolumab with other biologic therapies may increase the risk of serious infections.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: The concurrent use of anifrolumab with other biologic therapies is not recommended.(1) DISCUSSION: The combination of anifrolumab with other biologic therapies has not been studied and is not recommended.(1) |
SAPHNELO |
| Ritlecitinib/Immunosuppressives; Immunomodulators SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Ritlecitinib, immunosuppressives, and immunomodulators all suppress the immune system. CLINICAL EFFECTS: Concurrent use of ritlecitinib with immunosuppressives or immunomodulators may result in an increased risk of serious infections. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: The US manufacturer of ritlecitinib states that concurrent use of ritlecitinib with other JAK inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants is not recommended.(1) DISCUSSION: Serious infections have been reported in patients receiving ritlecitinib. Reported infections included appendicitis, COVID-19 infection (including pneumonia), and sepsis. Reports of viral reactivation, including herpes virus reactivation was reported in clinical studies with ritlecitinib.(1) |
LITFULO |
| Etrasimod/Immunosuppressives; Immunomodulators SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Etrasimod causes reversible sequestration of lymphocytes in lymphoid tissues, resulting in a mean 55% decrease in peripheral blood lymphocyte count at 52 weeks.(1) Other immunosuppressives and immune-modulators also suppress the immune system. CLINICAL EFFECTS: Concurrent use of etrasimod with immunosuppressive or immune-modulating agents may result in an increased risk of serious and fatal infections, such as disseminated herpetic infection, cryptococcal infection, or progressive multifocal leukoencephalopathy (PML).(1) PREDISPOSING FACTORS: Incomplete washout of previously prescribed immunosuppressive or immune-modulating medications increases the risk of adverse effects. PATIENT MANAGEMENT: The etrasimod US prescribing information states etrasimod has not been studied in combination with anti-neoplastic, immune-modulating, or immunosuppressive therapies. Concomitant administration of these therapies with etrasimod should be avoided because of the risk of additive immune effects during therapy and in the weeks following administration. Etrasimod's effect on peripheral lymphocytes may persist for up to 5 weeks after discontinuation.(1) When switching from drugs with prolonged immune effects, the half-life and mode of action of these drugs must be considered in order to avoid unintended additive immunosuppressive effects.(1) DISCUSSION: Fatal disseminated herpes zoster and herpes simplex infections, cryptococcal meningitis, disseminated cryptococcal infections, and cases of progressive multifocal leukoencephalopathy (PML) have been reported in patients treated with other sphingosine-1 phosphate receptor modulators.(1) |
VELSIPITY |
| Ropeginterferon alfa-2b/Slt Immunosuppress; Immunomodulator SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Ropeginterferon alfa-2b and immunosuppressives both suppress the immune system. CLINICAL EFFECTS: Concurrent use of ropeginterferon alfa-2b with immunosuppressives may result in an increased risk of serious infections. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Avoid concurrent use of myelosuppressive agents.(1-2) If concurrent use cannot be avoided, monitor for effects of excessive immunosuppression. DISCUSSION: In clinical trials, 20% of patients experienced leukopenia. Interferon alfa products may cause fatal or life-threatening infections.(1-2) |
BESREMI |
| Deuruxolitinib/Immunosuppressives; Immunomodulators SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Deuruxolitinib, immunosuppressives, and immunomodulators all suppress the immune system.(1) CLINICAL EFFECTS: Concurrent use of deuruxolitinib and potent immunosuppressants may increase the risk of serious infections.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: The US manufacturer of deuruxolitinib states that concurrent use of deuruxolitinib with other JAK inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants is not recommended.(1) If concurrent use cannot be avoided, patients should be monitored for signs and symptoms of infection. If a patient develops a serious or opportunistic infection, interrupt deuruxolitinib treatment until the infection is controlled. DISCUSSION: Serious infections have been reported in patients receiving treatment with deuruxolitinib.(1) |
LEQSELVI |
There are 6 moderate interactions.
The clinician should assess the patient’s characteristics and take action as needed. Actions required for moderate interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration.
| Drug Interaction | Drug Names |
|---|---|
| Ustekinumab/Immunosuppressives; Immunomodulators SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Ustekinumab, immunosuppressives, and immunomodulators all suppress the immune system.(1) CLINICAL EFFECTS: Concurrent use of ustekinumab with immunosuppressive or immunomodulating agents may result in an increased risk for serious infections.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: The US manufacturer of ustekinumab recommends caution because the concurrent use of ustekinumab with immunosuppressive agents may increase the risk of infection. If concurrent therapy is warranted, consider the risk of additive immune suppression and monitor based on prescribing information for both agents.(1) DISCUSSION: Ustekinumab has not been studied in combination with other immunosuppressants in psoriasis studies. In psoriatic arthritis studies, concomitant methotrexate use did not appear to influence the safety or efficacy of ustekinumab. In Crohn's disease and ulcerative colitis studies, concomitant use of immunosuppressants or corticosteroids did not appear to influence the safety or efficacy of ustekinumab. If concurrent therapy is warranted, consider the potential for increased immunosuppressive risks from both agents.(1) The most common infections reported by ustekinumab treated patients in the clinical trial periods included nasopharyngitis(8%) and upper respiratory tract infection(5%). Serious bacterial, mycobacterial, fungal, and viral infections were observed in patients receiving ustekinumab. Cases of interstitial pneumonia, eosinophilic pneumonia, and cryptogenic organizing pneumonia resulting in respiratory failure or prolonged hospitalization have been reported in patients receiving ustekinumab.(1) |
IMULDOSA, OTULFI, PYZCHIVA, PYZCHIVA AUTOINJECTOR, SELARSDI, STARJEMZA, STELARA, STEQEYMA, USTEKINUMAB, USTEKINUMAB-AAUZ, USTEKINUMAB-AEKN, USTEKINUMAB-TTWE, WEZLANA, YESINTEK |
| COVID-19 Vaccines/Immunosuppressives; Immunomodulators SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Immunosuppressants and immunomodulators may prevent the immune system from properly responding to the COVID-19 vaccine.(1-3) CLINICAL EFFECTS: Administration of a COVID-19 vaccine with immunosuppressants or immunomodulators may interfere with vaccine-induced immune response and impair the efficacy of the vaccine. However, patients should be offered and given a COVID-19 vaccine even if the use and timing of immunosuppressive agents cannot be adjusted.(1-3) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: The Centers for Disease Control and Prevention (CDC),(1) Infectious Diseases Society of America (IDSA),(2) and the American College of Rheumatology (ACR)(3) have published guidances for COVID-19 vaccination in patients on immunosuppressants. The CDC states that all immunocompromised patients over 6 months of age should receive at least 1 dose of COVID-19 vaccine if eligible. See the CDC's Interim Clinical Considerations for Use of COVID-19 Vaccines for specific recommendations based on age, vaccination history, and vaccine manufacturer.(1) The CDC advises planning for vaccination at least 2 weeks before starting or resuming immunosuppressive therapy.(1) IDSA recommends timing COVID-19 vaccination at least 2 weeks before starting or at least 3 months after completing immunosuppressive therapy.(2) The ACR states that in general, immunosuppressants and immunomodulators should be held for 1-2 weeks after each vaccine dose.(3) Patients should be offered and given a COVID-19 vaccine even if the use and timing of immunosuppressive agents cannot be adjusted, though the immune response will likely be blunted. COVID-19 vaccines should not be delayed in patients taking immunosuppressive therapies.(1-2) See below for specific recommendations for certain agents. B-cell depleting agents, including rituximab: The CDC states that the utility of B-cell quantification to guide clinical care is not known and is not recommended. Patients who receive B-cell depleting therapy on a continuing basis should receive COVID-19 vaccines about 4 weeks before the next scheduled dose. For patients who received 1 or more doses of COVID-19 vaccine during treatment with B-cell-depleting therapies that were administered over a limited period (e.g., as part of a treatment regimen for certain malignancies), revaccination may be considered according to the current CDC recommendations for unvaccinated patients. The suggested interval to start revaccination is about 6 months after completion of the B-cell-depleting therapy.(1) IDSA recommends waiting for at least 3-6 months after the last infusion of B-cell depleting therapy before administering COVID-19 vaccines.(2) The ACR recommends consulting with the rheumatologist to determine optimal timing of COVID-19 vaccination. Measuring CD19 B cells may be considered to determine need for a booster vaccine dose. If B cell levels are not measured, a supplemental vaccine dose 2-4 weeks before the next scheduled dose of rituximab is recommended.(3) Recipients of hematopoietic cell transplant or CAR-T-cell therapy who received one or more doses of COVID-19 vaccine prior to or during treatment should undergo revaccination following the current CDC recommendations for unvaccinated patients. Revaccination should start at least 3 months (12 weeks) after transplant or CAR-T-cell therapy.(1,2) The CDC includes abatacept, cyclophosphamide, and TNF-alpha and cytokine inhibitors in their general recommendation to hold therapy for at least 2 weeks following vaccination (1) while the ACR provides different recommendations:(3) *Abatacept: - Subcutaneous abatacept should be withheld for 1-2 weeks after each vaccine dose, as disease activity allows. - For intravenous abatacept, time administration so that vaccination will occur 1 week before the next abatacept infusion. *Cyclophosphamide: When feasible, administer cyclophosphamide 1 week after each COVID-19 vaccine dose. *TNF-alpha inhibitors and cytokine inhibitors: The ACR was not able to reach consensus on whether to modify dosing or timing of these agents with COVID-19 vaccination. DISCUSSION: IDSA recommendations are based on cohort and case control studies in immunocompromised patients that found low to modest vaccine effectiveness (37-61%) but lower risks of COVID-19 association hospitalization, COVID-19 related mortality, and critical illness.(2) The ACR convened a COVID-19 Vaccine Guidance Task Force to provide guidance on optimal use of COVID-19 vaccines in rheumatology patients. These recommendations are based on limited clinical evidence of COVID-19 vaccines in patients without rheumatic and musculoskeletal disorders and evidence of other vaccines in this patient population.(3) The ACR recommendation for rituximab is based on studies of humoral immunity following receipt of other vaccines. These studies have uncertain generalizability to vaccination against COVID-19, as it is unknown if efficacy is attributable to induction of host T cells versus B cell (antibody-based) immunity.(3) The ACR recommendation for mycophenolate is based on preexisting data of mycophenolate on non-COVID-19 vaccine immunogenicity. Emerging data suggests that mycophenolate may impair SARS-CoV-2 vaccine response in rheumatic and musculoskeletal disease and transplant patients.(3) The ACR recommendation for methotrexate is based on data from influenza vaccines and pneumococcal vaccines with methotrexate.(3) The ACR recommendation for JAK inhibitors is based on concerns related to the effects of JAK inhibitors on interferon signaling that may result in a diminished vaccine response.(3) The ACR recommendation for subcutaneous abatacept is based on several studies suggesting a negative effect of abatacept on vaccine immunogenicity. The first vaccine dose primes naive T cells, naive T cell priming is inhibited by CTLA-4, and abatacept is a CTLA-4Ig construct. CTLA-4 should not inhibit boosts of already primed T cells at the time of the second vaccine dose.(3) |
COMIRNATY 2025-2026 (12Y UP), COMIRNATY 2025-2026(5-11Y), MNEXSPIKE 2025-2026 (12Y UP), NUVAXOVID 2025-2026, SPIKEVAX 2025-2026 (12Y UP), SPIKEVAX 2025-2026 (6M-11Y) |
| Sarilumab/Immunosuppressives; Immunomodulators SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Sarilumab, immunosuppressives, and immunomodulators all suppress the immune system.(1) CLINICAL EFFECTS: Concurrent use of sarilumab with immunosuppressive or immunomodulating agents may result in an increased risk for serious infections.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: The US manufacturer of sarilumab recommends caution because the concurrent use of sarilumab with immunosuppressive agents may increase the risk of infection. If concurrent therapy is warranted, consider the risk of additive immune suppression and monitor based on prescribing information for both agents.(1) DISCUSSION: Sarilumab was studied as monotherapy and in combination with methotrexate or conventional disease modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis studies. Sarilumab has not been studied with biological DMARDs and concurrent use should be avoided. If concurrent therapy is warranted, consider the potential for increased immunosuppressive risks from both agents.(1) The most common infections reported by sarilumab treated patients in the clinical trial periods included pneumonia and cellulitis. Serious bacterial, mycobacterial, fungal, and viral infections were observed in patients receiving sarilumab. Cases of tuberculosis, candidiasis, and pneumocystis with sarilumab have been reported.(1) |
KEVZARA |
| Ublituximab/Immunosuppressives; Immunomodulators SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Ublituximab, immunosuppressives, and immunomodulators all suppress the immune system.(1) CLINICAL EFFECTS: Concurrent use of ublituximab with immunosuppressive or immunomodulating agents may result in an increased risk for serious infections.(1) PREDISPOSING FACTORS: Incomplete washout of previously prescribed immunosuppressive or immune-modulating medications. PATIENT MANAGEMENT: The US manufacturer of ublituximab recommends caution because the concurrent use of ublituximab with immunomodulating or immunosuppressive agents, including immunosuppressant doses of corticosteroids, may increase the risk of infection.(1) If concurrent therapy is warranted, consider the risk of additive immune suppression and monitor based on prescribing information for both agents. When switching from agents with immune effects, the half-life and mechanism of action of these drugs must be taken into consideration in order to prevent additive immunosuppressive effects.(1) DISCUSSION: The most common infections reported by ublituximab-treated patients in the clinical trial periods included upper respiratory tract infections and urinary tract infections. Serious, including life-threatening or fatal, bacterial and viral infections were observed in patients receiving ublituximab.(1) Serious and/or fatal bacterial, fungal, and new or reactivated viral infections have been associated with other anti-CD20 B-cell depleting therapies. There were no cases of progressive multifocal leukoencephalopathy (PML) reported during the clinical trials; however, there have been reports of PML during or following completion of other anti-CD20 B-cell depleting therapies.(1) |
BRIUMVI |
| Belimumab/Biologic Therapies SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Concurrent use of belimumab with other biologic therapies may result in additive or synergistic effects on the immune system.(1) CLINICAL EFFECTS: Concurrent use of belimumab with other biologic therapies may increase the risk of serious infections.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: The concurrent use of belimumab with other biologic therapies should be approached with caution.(1) DISCUSSION: In a randomized, double-blind, placebo-controlled trial, more patients who received belimumab and rituximab experienced serious adverse events, serious infections, and post-injection systemic reactions (22.2%, 9%, and 13.2%, respectively) than patients who received belimumab with placebo (13.9%, 2.8%, 9.7%) or standard therapy (19.7%, 5.3%, 5.3%).(1) The combination of belimumab with other biologic therapies has not been studied and should be used cautiously.(1) |
BENLYSTA |
| Cladribine Oncology Inj/Immunosuppressives; Immunomodulators SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Cladribine in combination with immunosuppressives and immune-modulators all suppress the immune system.(1-4) CLINICAL EFFECTS: Concurrent use of cladribine with immunosuppressive or immune-modulating agents may result in an increased risk of serious infections.(1-4) PREDISPOSING FACTORS: Incomplete washout of previously prescribed immunosuppressive or immune-modulating medications. PATIENT MANAGEMENT: Recommendations for cladribine regarding this interaction differ between regulatory approving agencies. The cladribine US, UK, and Australian prescribing information state: -Caution should be exercised if cladribine injection is administered before, after, or in conjunction with other drugs known to cause immunosuppression or myelosuppression.(1-3) The cladribine Canadian prescribing information states: -Proceed carefully in patients with severe bone marrow impairment of any etiology since further suppression of bone marrow function should be anticipated.(4) DISCUSSION: Severe bone marrow suppression, including neutropenia, anemia and thrombocytopenia, has been commonly observed in patients treated with cladribine injection, especially at high doses.(1-4) |
CLADRIBINE |
The following contraindication information is available for IMDELLTRA (tarlatamab-dlle):
Drug contraindication overview.
*None.
*None.
There are 1 contraindications.
Absolute contraindication.
| Contraindication List |
|---|
| Lactation |
There are 5 severe contraindications.
Adequate patient monitoring is recommended for safer drug use.
| Severe List |
|---|
| Anemia |
| Infection |
| Neutropenic disorder |
| Pregnancy |
| Thrombocytopenic disorder |
There are 0 moderate contraindications.
The following adverse reaction information is available for IMDELLTRA (tarlatamab-dlle):
Adverse reaction overview.
The most common adverse reactions (>20%) to tarlatamab-dlle were cytokine release syndrome, fatigue, pyrexia, dysgeusia, decreased appetite, musculoskeletal pain, constipation, anemia, and nausea. The most common Grade 3 or 4 laboratory abnormalities (>=5%) were decreased lymphocytes, decreased sodium, decreased total neutrophils, and increased uric acid.
The most common adverse reactions (>20%) to tarlatamab-dlle were cytokine release syndrome, fatigue, pyrexia, dysgeusia, decreased appetite, musculoskeletal pain, constipation, anemia, and nausea. The most common Grade 3 or 4 laboratory abnormalities (>=5%) were decreased lymphocytes, decreased sodium, decreased total neutrophils, and increased uric acid.
There are 20 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Cytokine release syndrome Immune effector cell-associated neurotoxicity syndrome Increased alanine transaminase Increased aspartate transaminase Lymphopenia |
Hyperbilirubinemia Hyperuricemia Hypokalemia Hyponatremia Infection Neutropenic disorder Pneumonia Thrombocytopenic disorder |
| Rare/Very Rare |
|---|
|
Acidosis Acute respiratory failure Encephalopathy Hypersensitivity drug reaction Pulmonary thromboembolism Seizure disorder Sepsis |
There are 18 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Anemia Anorexia Constipation Dysgeusia Fatigue Fever Musculoskeletal pain Nausea |
Ataxia Cough Delirium Dyspnea Oral candidiasis Pharyngitis Tremor Upper respiratory infection Urinary tract infection Weight loss |
| Rare/Very Rare |
|---|
| None. |
The following precautions are available for IMDELLTRA (tarlatamab-dlle):
The safety and effectiveness of tarlatamab-dlle have not been established in pediatric patients.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
Based on its mechanism of action, tarlatamab-dlle may cause fetal harm when administered to a pregnant woman. There are no available data on the use of tarlatamab-dlle in pregnant women to inform a drug-associated risk. Tarlatamab-dlle causes T-cell activation and cytokine release; immune activation may compromise pregnancy maintenance.
Human immunoglobulin G (IgG) and proteins comprising IgG-derived fragment crystallizable (Fc) domains are known to cross the placental barrier; therefore, tarlatamab-dlle has the potential to be transmitted from the mother to the developing fetus. Advise women of the potential risk to the fetus.
Human immunoglobulin G (IgG) and proteins comprising IgG-derived fragment crystallizable (Fc) domains are known to cross the placental barrier; therefore, tarlatamab-dlle has the potential to be transmitted from the mother to the developing fetus. Advise women of the potential risk to the fetus.
There are no data on the presence of tarlatamab-dlle in human milk or the effects on the breastfed child or on milk production. The effects of local GI exposure and limited systemic exposure in the breastfed child to tarlatamab-dlle are unknown. Because of the potential for serious adverse reactions in a breastfed child, advise patients not to breastfeed during treatment with tarlatamab-dlle and for 2 months after the last dose.
Of the 187 patients with small cell lung cancer (SCLC) who received tarlatamab-dlle 10 mg as a single agent, 51% were 65 years of age or older and 11% were 75 years of age or older. No overall differences in tarlatamab pharmacokinetics or safety were observed between older (>=65 years of age) and younger patients.
The following prioritized warning is available for IMDELLTRA (tarlatamab-dlle):
WARNING: Tarlatamab may cause a certain serious (even fatal) side effect known as cytokine release syndrome-CRS. Careful monitoring and prompt treatment may decrease your risk. Get medical help right away if you have symptoms such as fever, chills, headache, fast heartbeat, trouble breathing, nausea/vomiting, or dizziness/lightheadedness.
This medication can also cause serious (even fatal) nervous system problems. Tell your doctor right away if you have any symptoms such as confusion, drowsiness, numbness/tingling of arms/legs, mental/mood changes, trouble sleeping, shaking, loss of balance, trouble speaking and understanding, or seizures.
WARNING: Tarlatamab may cause a certain serious (even fatal) side effect known as cytokine release syndrome-CRS. Careful monitoring and prompt treatment may decrease your risk. Get medical help right away if you have symptoms such as fever, chills, headache, fast heartbeat, trouble breathing, nausea/vomiting, or dizziness/lightheadedness.
This medication can also cause serious (even fatal) nervous system problems. Tell your doctor right away if you have any symptoms such as confusion, drowsiness, numbness/tingling of arms/legs, mental/mood changes, trouble sleeping, shaking, loss of balance, trouble speaking and understanding, or seizures.
The following icd codes are available for IMDELLTRA (tarlatamab-dlle)'s list of indications:
| Extensive-stage small cell lung cancer | |
| C34 | Malignant neoplasm of bronchus and lung |
| C34.0 | Malignant neoplasm of main bronchus |
| C34.00 | Malignant neoplasm of unspecified main bronchus |
| C34.01 | Malignant neoplasm of right main bronchus |
| C34.02 | Malignant neoplasm of left main bronchus |
| C34.1 | Malignant neoplasm of upper lobe, bronchus or lung |
| C34.10 | Malignant neoplasm of upper lobe, unspecified bronchus or lung |
| C34.11 | Malignant neoplasm of upper lobe, right bronchus or lung |
| C34.12 | Malignant neoplasm of upper lobe, left bronchus or lung |
| C34.2 | Malignant neoplasm of middle lobe, bronchus or lung |
| C34.3 | Malignant neoplasm of lower lobe, bronchus or lung |
| C34.30 | Malignant neoplasm of lower lobe, unspecified bronchus or lung |
| C34.31 | Malignant neoplasm of lower lobe, right bronchus or lung |
| C34.32 | Malignant neoplasm of lower lobe, left bronchus or lung |
| C34.8 | Malignant neoplasm of overlapping sites of bronchus and lung |
| C34.80 | Malignant neoplasm of overlapping sites of unspecified bronchus and lung |
| C34.81 | Malignant neoplasm of overlapping sites of right bronchus and lung |
| C34.82 | Malignant neoplasm of overlapping sites of left bronchus and lung |
| C34.9 | Malignant neoplasm of unspecified part of bronchus or lung |
| C34.90 | Malignant neoplasm of unspecified part of unspecified bronchus or lung |
| C34.91 | Malignant neoplasm of unspecified part of right bronchus or lung |
| C34.92 | Malignant neoplasm of unspecified part of left bronchus or lung |
Formulary Reference Tool